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MNS blood group system: a review
M.E. Reid
The MNS blood group system is second only to the Rh blood group 
system in its complexity. Many alloantibodies to antigens in the 
MNS system are not generally clinically significant although anti-
bodies to low-prevalence and high-prevalence MNS antigens have 
caused hemolytic disease of the fetus and newborn. The MNS an-
tigens are carried on glycophorin A (GPA), glycophorin B (GPB), 
or hybrids thereof, which arise from single-nucleotide substitu-
tion, unequal crossing over, or gene conversion between the gly-
cophorin genes. Antigens in the MNS system are fully developed 
at birth. This review summarizes aspects of the MNS system, in-
cluding the molecular basis of some antigens in the MNS blood 
group system. Readers are referred to existing excellent reviews 
for background information.1–9 Throughout this document, infor-
mation given without references can be found in the reviews listed 
previously, and the reader is referred to these reviews for refer-
ences to original reports.
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History
After the discovery of the ABO antigens, Landsteiner and Levine reasoned that other variations among healthy humans existed. Thus, in 1927, they immu-
nized rabbits with human blood and, after absorption, dis-
covered antibodies that detected the M or the N antigen.10 
Because the antigens were clearly related but not exactly 
antithetical, they named them, respectively, after the sec-
ond and fifth letters of the word immune. Later anti-M and 
anti-N were found in human serum. In 1947, the S antigen 
was described; it was detected by an antibody in the serum 
of a patient from Sydney, Australia. Three years later, the 
antithetical antigen was described and, as was the con-
vention at the time, given the name s. The U antigen was 
described in 1953 and named from “the almost universal 
distribution” of the antigen. The other 41 antigens in the 
MNS blood group system are mostly named after the an-
tibody maker or the person whose red blood cells (RBCs) 
expressed the antigen.11 Table 1 lists the antigens, with their 
ISBT numbers,12,13 and relative prevalence. In various stud-
ies, M/N and S/s were shown to be in the same blood group 
system and to have linkage disequilibrium. The prevalence 
Review
Table 1. Antigens of the MNS blood group system





U MNS5 High 
He MNS6 Low 
Mia MNS7 Low 
Mc MNS8 Low 
Vw MNS9 Low 
Mur MNS10 Low 
Mg MNS11 Low 
Vr MNS12 Low 
Me MNS13 Low 
Mta MNS14 Low 
Sta MNS15 Low 
Ria MNS16 Low 
Cla MNS17 Low 
Nya MNS18 Low 
Hut MNS19 Low 
Hil MNS20 Low 
Mv MNS21 Low
Far MNS22 Low 
sD MNS23 Low 
Mit MNS24 Low 
Dantu MNS25 Low 
Hop MNS26 Low
Nob MNS27 Low 
Ena MNS28 High
ENKT MNS29 High
′N′ MNS30 High 
Or MNS31 Low 
DANE MNS32 Low 
TSEN MNS33 Low 
MINY MNS34 Low 
MUT MNS35 Low 
SAT MNS36 Low 
ERIK MNS37 Low 
Osa MNS38 Low 
ENEP MNS39 High
ENEH MNS40 High
HAG MNS41 Low 
ENAV MNS42 High
MARS MNS43 Low 
ENDA MNS44 High
ENEV MNS45 High
MNTD MNS46 Low 
Antigen ISBT number Prevalence
(continued)
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location of M/N on GPA is depicted in Figure 1, and the lo-
cation of ‘N’/He at the N-terminus, and S or s closer to the 
lipid bilayer of GPB, are shown in Figure 2. Figures 1 and 
2 also show the location of other antigens that result from 
a single amino acid change. Antigens carried on GPA and 
GPB hybrid molecules are listed in Table 5.
 The first 26 amino acids of GPAN and GPB are identical, 
and the weak N antigen expression of M+N– RBCs (called 
‘N’) is likely a consequence of the fewer GPB copies per RBC 
as compared with the number of copies of GPA per RBC. 
GPB has a shorter amino-terminal exofacial domain than 
does GPA and little or no cytoplasmic domain. There is evi-
dence that the exofacial domain of GPA interacts with RBC 
membrane skeletal proteins.19
 On intact RBCs, GPA is susceptible to cleavage by 
trypsin at amino acid 39; however, the α-chymotrypsin 
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Fig. 1 Schematic of 
GPA showing the loca-
tion of antigens that 
arise from simple amino 
acid changes. The 
trypsin and ficin/papain 
cleavage sites on intact 
RBCs are noted. De-
pending on the location 
of the antigenic determi-
nant, antibodies to high-
prevalence antigens 
on GPA are generically 




resistant). The line and 
ball at amino acid 26 
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*The numbers are compiled from numerous sources.
of the various combinations of M, N, S, and s antigens in 
Whites and Blacks is given in Table 2.
 The antigens of low prevalence result from single ami-
no acid changes or are on hybrid GPA/GPB molecules. For 
many years, a number of low-prevalence antigens in the 
MNS blood group system were grouped together in the 
so-called Miltenberger (Mi) subsystem.14,15 Originally, RBCs 
reactive with the serum containing anti-Mia were classified 
into four classes on the basis of their different reactions with 
four types of sera called Verweyst (Vw), Miltenberger (Mia), 
Murrell (Mur), and Hill (Hil). RBCs carrying some antigens 
assigned to the Miltenberger subsystem reacted with one or 
more of these three specific antisera yet failed to react with 
anti-Mia. For example, GP.Hil (Mi.V) RBCs reacted with 
anti-Hil, but not with anti-Mia (Table 3). The Miltenberger 
subsystem grew to 11 classes, which were defined by one 
or more determinants reacting with type-specific antisera 
(Table 3). As the complexity of the Miltenberger subsystem 
increased, further expansion was no longer feasible, desir-
able, or relevant. As all the antigens are in the MNS system, 
the recommendation was made to use “GP” for the glyco-
protein and GYP for the gene, with the abbreviated name of 
the propositus in whom the variant has been described, e.g., 
Mi.V became GP.Hil and the encoding gene is GYP.Hil. The 
Miltenberger subsystem is now considered obsolete.16,17
 
Glycophorin A and Glycophorin B
 Antigens in the MNS system are carried on GPA, GPB, 
or hybrids thereof. GPA and GPB are type I transmembrane 
sialoglycoproteins that traverse the RBC membrane lipid 
bilayer once and are orientated with their amino-termini 
to the outside of the RBC membrane. The amino-terminal 
domains of GPA and GPB both carry O-glycans, whereas 
only GPA carries an asparagine-linked–glycan (N-glycan), 
which is attached to amino acid residue 26.18 The M and N 
blood group polymorphism is the result of a different ami-
no acid sequence at the amino-terminus of GPA, whereas 
the S and s blood group polymorphism arises from a single 
amino acid substitution at residue 29 of GPB (Table 4). The 
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cleavage site is protected by local 
carbohydrate residues and, there-
fore, is relatively resistant to this 
enzyme. This explains why the M 
and N antigens are trypsin-sensitive 
but α-chymotrypsin–resistant. In 
contrast, on intact RBCs, GPB is 
resistant to trypsin cleavage but 
sensitive to α-chymotrypsin cleav-
age (at amino acid 32), which ac-
counts for the trypsin-resistant, 
α-chymotrypsin–sensitive prop-
erties of its ‘N’, S, and s antigens 
(Figs. 1 and 2).
Function of Glycophorin A and 
Glycophorin B
 GPA (CD235A) and GPB 
(CD235B) contribute most of the car-
bohydrate on the RBC membrane. 
The O-glycans on these two gly-
cophorins carry most of the sialic acid and contribute to 
the net negative charge of the RBC. The negatively charged 
glycocalyx keeps RBCs from sticking to each other and 
to the endothelial cells of the blood vessels2,18 and pro-
tects the RBC from invasion by bacteria and other patho-
gens.20,21 GPA-deficient RBCs are more resistant to inva-
sion by Plasmodium falciparum merozoites because sialic 
acid appears to be essential for adhesion of the parasite to 
the RBC.22–25 The sialic acid attached to GPA and GPB has 
been reported to be the target of the influenza virus20 and 
the encephalomyocarditis virus.26 It has also been demon-
strated that GPA plays a role in chaperoning band 3 trans-
port to the RBC membrane.27,28 An absence of GPA or GPB, 
or GPA and GPB, from RBCs (En(a–), S–s–, and MkMk, 
phenotypes, respectively) does not result in altered RBC 
morphology, and individuals with these phenotypes do not 
have significant physiologic abnormalities.
Glycophorin Gene Family
 The genes encoding GPA (GYPA) or GPB (GYPB) and 
GPE glycophorin (GYPE) are homologous and reside in 
an approximately 350-kb gene cluster (5′-GYPA-GYPB-
GYPE-3′) on 4q28–q31.29 GYPA has seven exons, GYPB 
has six exons (of which exon 3 is a pseudo or a noncod-
ing exon), and GYPE also has six exons (of which exons 
3 and 4 are pseudo-exons). For GYPA and GYPB genes, 
exons 1 and 2 encode a leader sequence, exons 2 through 4 
encode the extracellular domains, and exon 5 encodes the 
transmembrane domains. Exon 6 and part of the 5′ end of 
exon 7 of GYPA encode the cytoplasmic domain of GPA. 
If GYPE encodes a membrane-bound product (this is still 
controversial), it would be a short sialoglycoprotein with 
the M antigen at its amino-terminus.



























GP.Vw Mi.I + + 0 0 0 0 0 0 0 0 0
GP.Hut Mi.II + 0 0 + 0 0 0 0 0 0 +
GP.Mur Mi.III + 0 + 0 + 0 0 0 0 + +
GP.Hop Mi.IV + 0 + 0 0 + 0 0 + + +
GP.Hil Mi.V 0 0 0 0 + 0 0 0 0 + 0
GP.Bun Mi.VI + 0 + 0 + + 0 0 0 + +
GP.Nob Mi.VII 0 0 0 0 0 0 + 0 0 0 0
GP.Joh Mi.VIII 0 0 0 0 0 + + 0 0 0 0
GP.Dane Mi.IX 0 0 + 0 0 0 0 + 0 0 0
GP.HF Mi.X + 0 0 0 + 0 0 0 0 + +
GP.JL Mi.XI 0 0 0 0 0 0 0 0 + + 0
 The high degree of sequence homology and organization 
along the chromosome may be responsible for the relatively 
frequent occurrence of unequal homologous recombina-
tions and gene conversions among the three GYP genes. A 
number of the resulting glycophorin products show variant 
blood group phenotypes whose molecular studies, in turn, 
led to the documentation of gene rearrangements (Tables 5 
and 6).11,30
GYP Gene Deletions Giving Rise to Null Phenotype RBCs
 The various deletions that give rise to the rare null phe-
notypes, En(a–)Fin, S–s–U–, and MkMk, are summarized 
in Table 7. It should be noted that deletion is not the only 
mechanism by which the En(a–) and S–s–U– phenotypes 
can arise.31–33 RBCs from individuals with the En(a–) Fin 
phenotype lack GPA and, thus, all antigenic determinants 
associated with GPA. RBCs from individuals with the S–s–
U– phenotype lack GPB and, thus, all antigens carried on 
this glycophorin. RBCs from people with the MkMk pheno-
type lack both GPA and GPB, and thus lack M, N, Ena, S, s, 
and U blood group antigens.





M GYPAM GPAM 1 Ser, 5 Gly
N GYPAN GPAN 1 Leu, 5 Glu
S GYPBS GPBS 29 Met
s GYPBs GPBs 29 Thr
Table 3. GP classification and associated antigens of the obsolete Miltenberger subsystem 
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Molecular Bases of Glycophorin Variants and Antigens
 RBCs with altered glycophorin molecules may be de-
tected in a variety of ways. The M, N, S, or s antigens are 
expressed more strongly or more weakly than controls and 
are unexpectedly sensitive or resistant to treatment by dif-
ferent enzymes; there is a loss of a high-prevalence anti-
gen or appearance of a low-prevalence antigen. Analysis by 
SDS-polyacrylamide gel electrophoresis is a useful tool to 
reveal a change in mobility caused by either a new glyco-
phorin molecule or a change in glycosylation.
 Variant GYP genes arise from a nucleotide substitution 
or substitutions, unequal crossover, or gene conversion. 
These GYP gene rearrangements have given rise to the anti-
genic diversity of the MNS blood group system.9,11,30 See the 
NCBI Web site ‘dbRBC’ (www.ncbi.nlm.nih.gov/gv/rbc) for 
a list of reported alleles.
 Nucleotide substitutions giving rise to MNS antigens 
are shown in Figures 1 and 2.
Single crossover
 A crossover (a mutual exchange of nucleotides between 
misaligned homologous genes with generation of two 
recombinants in reciprocal arrangement) can occur 
between GYPA and GYPB if the chromosomes misalign 
during meiosis. A chromosome carrying the hybrid GYP(A-
B) gene does not have GYPA or GYPB genes (Lepore type), 
whereas the reciprocal product is a chromosome carrying a 
hybrid GYP(B-A) gene as well as normal GYPA and GYPB 
genes (anti-Lepore type). The novel amino acid sequences 
encoded by nucleotides at the junctions may be recognized 
by antibodies in human serum. Examples of Lepore type 
and anti-Lepore type GYP genes, variant glycophorins, and 
the antigens expressed are given in Table 5.5
   
Double crossover
 This mechanism also involves a mutual exchange of 
nucleotides and generation of two reciprocal recombinant 
genes. As a consequence of this mechanism, chromosomes 
carrying a GYP(A-B-A) gene also carry a normal GYPB gene 
and the reciprocal chromosome bears a GYP(B-A-B) gene and 
a normal GYPA gene. Such genes can also arise through gene 
conversion and although currently there is no way to prove 
which mechanism gives rise to the GP(A-B-A) or GP(B-A-B) 
hybrid gene, the favored mechanism is gene conversion.
M.E. Reid
Table 5. Hybrid alleles, glycophorins, phenotypes, and associated low-prevalence antigens
Allele Glycophorin Phenotype Antigens on hybrid
GYP(A-B) GP(A-B) GP.Hil Hil, MINY
GP.JL TSEN, MINY
GP.TK SAT
GYP(B-A) GP(B-A) GP.Sch (Mr) Sta
GP.Dantu Dantu
GYP(A-B-A) GP(A-B-A) GP.Mg Mg
GP.KI Hil
GP.SAT SAT
GYP(B-A-B) GP(B-A-B) GP.Mur Mia, Mur, MUT, Hil, MINY
GP.Bun Mia, Mur, MUT, Hop, Hil, 
MINY
GP.HF Mia, MUT, Hil, MINY
GP.Hop Mia, Mur, MUT, Hop, TSEN, 
MINY
GP(A-B) GP.He (P2, NY, GL) He
GYP(B-A-ψB-A) GP(A-A) GP.Cal He, Sta
GYP(A-ψB-A) GP(A-B-A) GP.Vw Mia, Vw




GP(A-A) GP.Zan (MZ) Sta
GYPA 179G>A GPA GP.EBH ERIK encoded by one 
transcript
GP(A-A) GP.EBH Sta encoded by a second 
transcript 
GYP(A-ψE-A) GP(A-A) GP.Mar Sta
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Gene conversion
 Gene conversion can occur during the process of DNA 
repair between homologous genes.34 This mechanism re-
flects a directional transfer of nucleotides from one duplex 
to another and does not result in a reciprocal product. In 
eukaryotes, if adjacent, homologous genes misalign during 
meiosis, nucleotides from one gene can be inserted into one 
strand of DNA of the other gene. If this strand is the coding 
strand, then a hybrid gene will be formed.4,5
 Gene conversion can cause an insert of nucleotides from 
GYPA into the GYPB gene or an insertion of nucleotides 
from GYPB into the GYPA gene. A chromosome carrying 
a GYP(B-A-B) gene that is a result of this mechanism will 
also carry a normal GYPA gene. Similarly, a chromosome 
carrying a GYP(A-B-A) gene will also carry a normal GYPB 
gene (Table 8). During gene conversion, a splice sequence 
may be altered so that part of the GYPB pseudo-exon 3 is 
encoded. Gene conversion gives rise to hybrid genes that 
encode novel glycophorin molecules carrying certain low-
incidence antigens in the MNS blood group system (Tables 
5 and 6).4,5,9 When studying samples with variant glyco-
phorins, it is important to consider the products of genes 
carried on the partner in trans chromosome, which usually 
is wild-type GYPA and GYPB genes.
Antigens associated with altered glycosylation
 Several antigens associated with MNS have not been 
assigned numbers by the ISBT Working Party. For exam-
ple, M
1
 and Can, which are located within the N-terminal 
31 amino acid residues of GPAM, and Tm, Sj, Hu, and Sext, 
which are located within the N-terminal domain of GPAN, 
have not been assigned numbers yet. Antibodies to these 
antigens are not completely specific and exhibit weak affin-
ity for, respectively, GPB and GPA. They react with excep-
tional examples of, respectively, M–N+ and M+N– RBCs 
with a high level of GlcNAc-containing O-glycans.35
Clinical Relevance
 Antibodies to antigens in the MNS blood group system 
are often “naturally occurring” and if they do not react at 
37°C can be ignored in transfusion practice. Rare examples 
of anti-M and anti-N have been reported to cause immediate 
and delayed hemolytic transfusion reactions and hemolytic 
disease of the fetus and newborn (HDFN). Clinically signifi-
cant anti-N are most likely found in people with the M+N–
U– phenotype, and thereby detect GPB as well as N on GPA. 
Anti-M is often cold-reacting IgG and is enhanced by testing 
in an acidified environment.36 Some anti-M and anti-N only 
react with RBCs previously exposed to glucose.37–39 In the 
late 1970s, as many as a third of kidney dialysis patients us-
ing formaldehyde-sterilized dialysis membranes had anti-
Nf, regardless of their MN phenotype.40,41 This phenomenon 
is rarely seen today because formaldehyde sterilization was 
discontinued in dialysis practices after the reason for the 
presence of anti-Nf was delineated.42 Anti-S, -s, and anti-
U have been implicated in hemolytic transfusion reactions 
(immediate and delayed) and in HDFN.  Antibodies to many 
low-prevalence antigens in the MNS system have caused 
HDFN; in fact, that is typically how they are detected. Of 
particular note is the clinical importance of allo-anti-Ena, 
which has caused hemolytic transfusion reactions,43,44 and 
auto-anti-Ena, which has caused severe and fatal autoim-
mune hemolytic anemia.45–47
Concluding Remarks
 The MNS blood group system, with 46 antigens, is sec-
ond in its diversity only to the Rh system (with 50 antigens). 
Both systems are encoded by homologous genes: in the 
MNS system, GYPA and GYPB, and in the Rh system, RHD 
Table 6. Molecular mechanisms and associated antigens
Molecular mechanism Associated antigens*
Single nucleotide substitution GPA: Vr, Mta, Ria, Nya, Or, ERIK, 
Osa, ENEP/HAG, ENAV/MARS, 
ENEV, MNTD
GPB: S/s, Mv, sD, Mit
Two or more nucleotide substitution GPA: M/N
GPB: ‘N’
Unequal crossing over Sta, Dantu, Hil, TSEN, MINY, SAT
Gene conversion He, Mia, Mc, Vw/Hut/ENEH, Mur, 
Mg, Me, Sta, Hil, Hop, Nop, DANE, 
MINY, MUT, ENDA
*Ena and U antigens are not listed.
Table 7. Molecular basis of null phenotype RBCs
Null phenotype RBCs Molecular basis
En(a–)Fin Deletion of GYPA (exon 2 to 7) and 
GYPB (exon 1)
S–s–U– (deletion type) Deletion of GYPB (exon 2 to 6) 
and GYPE (exon 1)
MkMk Deletion of GYPA (exon 2 to 7), 
GYPB (exon 1 to 6), and GYPE 
(exon 1)
Table 8. Mechanisms giving rise to variant GYP genes and their in 
cis partner genes*
Mechanism for 
variant GYP gene Variant GYP gene GYP gene(s) in cis
Single crossover 
(Lepore)
GY(A-B) No GYPA or GYPB
Single crossover  
(anti-Lepore)
GY(B-A) GYPA and GYPB




*Note that the in trans partner chromosome will bear whichever 
GYP genes were inherited (most likely GYPA and GYPB).
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and RHCE. Thus, the antigens are not only a consequence 
of amino acid changes but also a result of novel sequences 
induced by rearranged genes. The GYPA, GYPB, and GYPE 
gene cluster is prone to mutation by radiation; there is a 
high incidence of somatic mutation events in atomic bomb 
survivors, in people exposed to accidental radiation, in pa-
tients with Bloom’s syndrome, and in patients receiving ra-
diation therapy. The mutation events were dose dependent; 
the greater the exposure, the greater proportion of RBCs 
exhibited mutations.48–51
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